These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35692348)

  • 21. Hidden Imputations and the Kaplan-Meier Estimator.
    Cole SR; Edwards JK; Naimi AI; Muñoz A
    Am J Epidemiol; 2020 Nov; 189(11):1408-1411. PubMed ID: 32412079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generalized Redistribute-to-the-Right Algorithm: Application to the Analysis of Censored Cost Data.
    Chen S; Zhao H
    J Stat Theory Pract; 2013 Apr; 7(2):. PubMed ID: 24403869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Displaying survival of patient groups defined by covariate paths: Extensions of the Kaplan-Meier estimator.
    Jay M; Betensky RA
    Stat Med; 2021 Apr; 40(8):2024-2036. PubMed ID: 33530128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved confidence intervals for a difference of two cause-specific cumulative incidence functions estimated in the presence of competing risks and random censoring.
    Scosyrev E
    Biom J; 2020 Oct; 62(6):1394-1407. PubMed ID: 32227361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data.
    Xie J; Liu C
    Stat Med; 2005 Oct; 24(20):3089-110. PubMed ID: 16189810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Focused Information Criterion for Restricted Mean Survival Times: Non-Parametric or Parametric Estimators.
    Nemes S; Gustavsson A; Jauhiainen A
    Entropy (Basel); 2022 May; 24(5):. PubMed ID: 35626596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A partially parametric estimator of survival in the presence of randomly censored data.
    Klein JP; Lee SC; Moeschberger ML
    Biometrics; 1990 Sep; 46(3):795-811. PubMed ID: 2242415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonparametric estimators of survival function under the mixed case interval-censored model with left truncation.
    Shen PS
    Lifetime Data Anal; 2020 Jul; 26(3):624-637. PubMed ID: 31930441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating medical care costs under conditions of censoring.
    Raikou M; McGuire A
    J Health Econ; 2004 May; 23(3):443-70. PubMed ID: 15120465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing.
    Rosen K; Prasad V; Chen EY
    Eur J Cancer; 2020 Dec; 141():152-161. PubMed ID: 33160265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survivor function estimators under group sequential monitoring based on the logrank statistic.
    Gorfine M
    Lifetime Data Anal; 2003 Jun; 9(2):175-93. PubMed ID: 12735495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating Left-Censored Data Through Substitution, Parametric, Semi-parametric, and Nonparametric Methods: A Simulation Study.
    Tekindal MA; Erdoğan BD; Yavuz Y
    Interdiscip Sci; 2017 Jun; 9(2):153-172. PubMed ID: 26590921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regression models for the restricted residual mean life for right-censored and left-truncated data.
    Cortese G; Holmboe SA; Scheike TH
    Stat Med; 2017 May; 36(11):1803-1822. PubMed ID: 28106926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
    Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
    BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved methods of estimating survival probabilities applied to renal transplant data.
    Grouven U; Schultz A; Pichlmayr R
    Int J Biomed Comput; 1994; 37(3):205-9. PubMed ID: 7705903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomes.
    De Backer M; Legrand C; Péron J; Lambert A; Buyse M
    Pharm Stat; 2023 Mar; 22(2):284-299. PubMed ID: 36321470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Look left, look right: censoring in clinical research.
    Groenwold RHH; Dekkers OM
    Eur J Endocrinol; 2023 Nov; 189(5):E1-E3. PubMed ID: 37956460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.
    Stegherr R; Schmoor C; Beyersmann J; Rufibach K; Jehl V; Brückner A; Eisele L; Künzel T; Kupas K; Langer F; Leverkus F; Loos A; Norenberg C; Voss F; Friede T
    Trials; 2021 Jun; 22(1):420. PubMed ID: 34187527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Projecting the standard error of the Kaplan-Meier estimator.
    Cantor AB
    Stat Med; 2001 Jul; 20(14):2091-7. PubMed ID: 11439423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Smooth estimation of the reliability function.
    Kulasekera KB; Williams CL; Coffin M; Manatunga A
    Lifetime Data Anal; 2001 Dec; 7(4):415-33. PubMed ID: 11763547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.